By staff writers

August 2, 2016 -- Pharmaceutical developer Mallinckrodt's Nuclear Imaging business segment produced lower revenues in its 2016 fiscal third quarter.

For the period (end-June 24), the company recorded Nuclear Imaging segment sales of $104 million, down 4.4% on a nominal basis and down 4.7% on a constant-currency basis from the $108.8 million reported in the third quarter of 2015.

Copyright © 2016

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking